Hüseyin Murat MUTUŞ, Mustafa Asım YÖRÜK, Gunes FEYİZOGLU, Çetin TİMUR

Prognostic factors and outcome of ABVD chemotherapy in childhood Hodgkin Iymphoma: A single center experience

Aim: The aim was to analyze the outcome of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vinblastine,and dacarbazine (ABVD) chemotherapy + adjuvant radiotherapy according to the risk groups and determine the adverse prognosticfactors affecting survival in Hodgkin lymphoma.Material and Methods: A retrospective study was performed on 52 pediatric patients with Hodgkin lymphoma who were treated withABVD between 1997 and 2018. Patients with early-stage favorable disease received 4 cycles of ABVD + radiotherapy. Early-stageunfavorable and advanced-stage patients received 6 cycles of ABVD + radiotherapy.Results: Thirty (57.7%) boys and 22 (42.3%) girls were included in the study. The median age of the patients was 9 years and 3months (1 year and 10 month – 17 years and 7 months). Overall survival rate was 94.2% and the mean survival time was 19.5±0.70(95% CI, 18.1 - 20.9) years. The mean event-free survival time was 9.5±6.5 years. Overall survival rate was 90%, and the meanevent-free survival time was 8.2±6.1 years in early-stage favorable disease. Overall survival rate was 100%, and the mean eventfreesurvival time was 1.9±7.0 years in early-stage unfavorable disease. Overall survival rate was 94.1 %, and the mean event-freesurvival time was 8.9±6.3 years in advanced-stage disease. Presence of bulky disease, nodular sclerosing histologic subtype andleukocytosis had a negative prognostic effect on relapse and bulky disease had adverse effect on overall survival (p

PDF

___

1. Bonadonna G, Viviani S, Bonfante V, et al. Survival in Hodgkin’s disease patients - report of 25 years of experience at the milan cancer institute. Eur J Cancer 2005;41:998- 1006.
2. Meyer RM, Gospodarowicz MK, Connors JM, et al: NCIC Clinical trials group; eastern cooperative oncology group. abvd alone versus radiation-based therapy in limited-stage hodgkin’s lymphoma. N Engl J Med 2012;366:399-408.
3. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 1996;14:1421-30.
4. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
5. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684-91.
6. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011;29:4227-33.
7. Carde P, Karrasch M, Fortpied C, et al. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016;34:2028-36.
8. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:1622-8.
9. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363:640-52.
10. Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin’s Disease: Multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000;6:1150-60.
11. Celkan T, Baris S, Ozkan A, ve ark. Çocukluk çağı Hodgkin lenfomanın seyri ile hematolojik ve diğer değişkenlerin ilişkisi Turk Arch Ped 2008;43:46-9.
12. Garcia R, Hernandez JM, Caballero MD, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer 1993;68:1227-31.
13. Glimelius I, Molin D, Amini RM, et al. Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haematol 2003;71:327-33.
14. Hasenclever D, Diehl V. A prognostic score for advanced hodgkin’s disease: international prognostic factors project on advanced hodgkin’s disease. N Engl J Med 1998;339:1506-14.
15. Ries LA, Kosary CL, Hankey BF, eds. SEER cancer statistics review 1973–1995. National Cancer Institute, Bethesda (MD); 1998.
16. Cavdar AO, Tacoy A, Babacan E, et al. Hodgkin’s disease in Turkish children: A clinical and histopathological analysis. J Natl Cancer Inst 1977;58:479-81.
17. Buyukpamukcu M, Atahan L, Caglar M, et al. Hodgkin’s disease in Turkish children: clinical characteristics and treatment results of 210 patients. Pediatr Hematol Oncol 1999;16:119-29.
18. Nachman JB, Sposto R, Herzog P, et al; Children’s Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-71.
19. Pötter R. Paediatric Hodgkin’s disease. Eur J Cancer 1999;35:1466-76.
20. Hudson MM, Onciu M, Donaldson SS. Hodgkin lymphoma. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:694-721.
21. Oguz A, Karadeniz C, Okur FV, et al. Prognostic factors and treatment outcome in childhood hodgkin disease. Pediatr Blood Cancer 2005;45:670-5.
22. Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin lymphoma study group. Blood 2000;96:1280-6.
23. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009;114:2051-9.
24. Bhethanabhotla S, Jain S, Kapoor G, et al. Outcome of pediatric advanced hodgkin iymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma 2017;58:1617-23.
25. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990–2004. J Natl Cancer Inst 2008;100:1271-3.
26. Andreas Engert. XVII. Treatment of advanced-stage Hodgkin lymphoma. Hematol Oncol 2015;33:87-9.
27. Colpo A, Hochberg E, Chen YB. Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma. Oncologist 2012;17:80-90.
28. Broccoli A, Zinzani PL. The role of transplantation in Hodgkin lymphoma. Br J Haematol 2019;184:93-104.